VPA and WT161 downregulate the expression of multiple HDACs and affect the expression of APP and APP secretases (BACE1, PSEN1, ADAM10), reducing Aβ deposition in AD cell and mouse models [193]. Here, CTSB is linked to Alzheimer disease.